期刊文献+

维持性血液透析患者采用不同抗凝剂封存Cuff导管的临床对照观察 被引量:14

The comparing study of sodium citrate and heparin in locking central vein hemodialysis catheter
下载PDF
导出
摘要 目的:观察在长期带Cuff中心静脉导管患者封管时枸橼酸钠与肝素钠的有效性和安全性等疗效。方法:选择2011年6月至2012年12月期间于四川大学华西医院行长期带Cuff颈内静脉导管的透析患者,收集患者的一般临床资料、导管相关性感染(CRIs)和导管内血栓等情况。结果:研究收集97例患者,平均年龄54.9±14.5岁。肝素组患者中出现CRIs的例数明显多于枸橼酸钠组(2.49 vs 1.01/1 000导管日);在需使用尿激酶封管溶栓的患者中,枸橼酸钠组高于肝素钠组且有统计学差异(P<0.05)。结论:与肝素钠相比,枸橼酸钠用于Cuff中心静脉导管封管时可减少CRIs的发生,同时可能升高其导管内血栓形成风险。 Objective:To observe the long-term efficacy and safety of citrate and heparin in locking central venous hemodialysis catheter. Methodology:during June 2011 to December 2012, in a cohort of ninety seven hemodialysis patients with cuffed catheter in right jugular vein were enrolled into this study. According to the way of locking central vein hemodialysis catheter, they were divided into heparin group (5% heparin, n= 55) and sodium citrate group (4% sodium citrate, n = 42)o The catheter-related infections (CRIs), side effects and catheter patency was accessed and compared between two groups. Results : CRIs were higher significantly in heparin group than that in sodium citrate group (2.49 vs 1.01/ 1000 catheter-day) ; but patients in sodium citrate group had a lower catheter patency rate than those in heparin group (P〈0.05). Conclusion:4% sodium citrate would be effective in lowing the occurrence of CRIs, but may be increase the risk of catheter thrombosis compared with 5% heparin.
出处 《肾脏病与透析肾移植杂志》 CAS CSCD 北大核心 2014年第6期539-542,共4页 Chinese Journal of Nephrology,Dialysis & Transplantation
基金 十二五国家科技支撑项目(2011BAI10B08)
关键词 维持性血液透析 中心静脉导管 枸橼酸钠 抗凝 maintenance hemodialysis central venous catheter citrate heparin
  • 相关文献

参考文献18

  • 1Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis,2001,32(9) : 1249-1272.
  • 2Lok CE, Mokrzycki MH. Prevention and management of catheter- related infection in hemodialysis patients. Kidney Int, 2010,79 ( 6 ) : 587-598.
  • 3Bessias N, Paraskevas KI, Tziviskou E, et al.Vascular access in elderly patients with end-stage renal disease.Int Urol Nephrol,2008,40(4) : 1133-1142.
  • 4Hemmelgarn BR, Moist LM, Lok CE, et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med,2011,364(4) :303-312.
  • 5Vascular Access Work Group.Clinical practice guidelines for vascular access.Am J Kidney Dis, 2006,48 (Suppl 1 ) :S248-273.
  • 6Ethier J, Mendelssohn DC, Eider S J, et al. Vascular access use and outcomes:an international perspective from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant, 2008, 23 ( 10 ) : 3219-3226.
  • 7O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis, 2011,52(9) :e162-193.
  • 8Blankestijn PJ.Treatment and prevention of catheter-related infections in baemodialysis patients. Nephrol Dial Transplant, 2001,16 ( 10 ) : 1975-1978.
  • 9Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant,2004,19(6) : 1546-1551.
  • 10Saltissi D, Morgan C, Westhuyzen J, et al. Comparison of low- molecular-weight heparin (enoxaparin sodium ) and standard unfractionated heparin for haemodialysis anticoagulation.Nephrol Dial Transplant, 1999,14 ( 11 ) :2698-2703.

同被引文献113

引证文献14

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部